Levodropropizina Fg (Levodropropizine)

Levodropropizine acts peripherally on sensory C‑fibers in the respiratory mucosa, dampening the afferent signals that trigger the cough reflex. By decreasing this peripheral input, the drug lowers cough frequency without significant central nervous system involvement.

The exact dose of levodropropizine is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of cough, and overall health status. Prescribers follow local labeling and clinical guidelines to select an appropriate regimen.

Safety data for levodropropizine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike central‑acting agents such as codeine, levodropropizine works peripherally, offering cough relief with a lower risk of sedation, respiratory depression, and dependence. This makes it a suitable option for patients who need symptom control without the central side effects associated with opioid‑based suppressants.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Levodropropizina Fg is taken orally. The dosage form should be swallowed with a glass of water, and it may be taken with or without food according to the prescriber’s instructions. Patients should follow the exact administration guidance provided on the label.

The most serious risks include allergic reactions such as rash, itching, swelling, or anaphylaxis, and severe gastrointestinal disturbances like persistent vomiting or diarrhea. Patients should seek immediate medical attention if they experience any of these symptoms.

Levodropropizine should be avoided in individuals with known hypersensitivity to the active ingredient, infants younger than 2 years unless specifically advised, and patients with severe hepatic or renal impairment unless a healthcare professional determines that the benefits outweigh the risks.